- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01737762
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
June 27, 2017 updated by: Healthpoint
A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S. Food and Drug Administration (FDA).
At least 250 subjects will participate. The study is going to be conducted in approximately 50 sites in the United States and Canada.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research is being done to compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure over the 16-week treatment period.
Vehicle looks the same as HP802-247 but contains no cells.
Target wound status is evaluated at each study visit (closed, open, reopened).
At wound closure or completion of treatment all subject will enter an observational safety followed up period which ends at one year after initial exposure to test article.
Study Type
Interventional
Enrollment (Actual)
155
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2T5C7
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A1R9
-
-
Ontario
-
Hamilton, Ontario, Canada, L8R2R3
-
London, Ontario, Canada, N6C5J1
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H5N4
-
-
-
-
-
San Juan, Puerto Rico, 00909-1711
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
-
Phoenix, Arizona, United States, 85015
-
Phoenix, Arizona, United States, 85006
-
-
California
-
Carlsbad, California, United States, 92009
-
Castro Valley, California, United States, 94546
-
Fair Oaks, California, United States, 95608
-
Fresno, California, United States, 93720
-
Laguna Hills, California, United States, 92653
-
Long Beach, California, United States, 90822
-
Los Angeles, California, United States, 90095
-
San Diego, California, United States, 92013
-
Sylmar, California, United States, 91342
-
-
District of Columbia
-
Washington, D.C., District of Columbia, United States, 20007
-
-
Florida
-
Hialeah, Florida, United States, 33013
-
Miami, Florida, United States, 33125
-
South Miami, Florida, United States, 33143
-
-
Illinois
-
Chicago, Illinois, United States, 60611
-
Jacksonville, Illinois, United States, 62650
-
Springfield, Illinois, United States, 62702
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
-
-
Michigan
-
Saginaw, Michigan, United States, 48602
-
-
Missouri
-
Washington, Missouri, United States, 63090
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
-
-
New Jersey
-
Bayonne, New Jersey, United States, 07002
-
Hoboken, New Jersey, United States, 07030
-
-
New York
-
East Meadow, New York, United States, 11554
-
New York, New York, United States, 10025
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
-
-
Ohio
-
Akron, Ohio, United States, 44307
-
Willoughby, Ohio, United States, 44094
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74127
-
-
Pennsylvania
-
Dunmore, Pennsylvania, United States, 18512
-
Wyomissing, Pennsylvania, United States, 19610
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37909
-
-
Texas
-
Fort Worth, Texas, United States, 76107
-
-
Washington
-
Tacoma, Washington, United States, 98431
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provide informed consent.
- Age ≥ 18 years and of either sex.
- Willing to comply with protocol instructions, including allowing all study assessments.
- Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area >12 cm2 to ≤ 36 cm2
- Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.
- Arterial supply adequacy confirmed
- Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.
- Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).
- Acceptable state of health and nutrition
Exclusion Criteria:
- History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.
- Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.
- Therapy with another investigational agent within thirty (30) days of Screening, or during the study.
- A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).
- Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.
- Refusal of or inability to tolerate compression therapy.
- Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.
- History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).
- Any prior exposure to HP802-247 or its vehicle.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HP802-247
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 solution) containing 0.5 x 106 cells per mL every 14 days.
|
HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
|
Placebo Comparator: Vehicle
Vehicle Control(fibrinogen solution & thrombin solution without cells)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wound Closure
Time Frame: 16 Weeks
|
Compare HP802-247 plus compression therapy against Vehicle plus compression therapy for proportion of subjects with complete wound closure over the 16-week treatment period from baseline.
|
16 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in Days to Closure
Time Frame: 16 Weeks
|
Compare the efficacy of HP802-247 plus compression therapy against Vehicle plus compression therapy in achieving complete wound closure, based on time in days to closure over the 16-week treatment period from baseline.
|
16 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: William Marston, MD, University of North Carolina
- Principal Investigator: Robert Kirsner, MD, University of Miami
- Study Director: Tommy Lee, MSHS, Healthpoint
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2012
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
November 20, 2012
First Submitted That Met QC Criteria
November 29, 2012
First Posted (Estimate)
November 30, 2012
Study Record Updates
Last Update Posted (Actual)
July 26, 2017
Last Update Submitted That Met QC Criteria
June 27, 2017
Last Verified
September 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 802-247-09-031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Results summaries have been sent to each site for distribution to participants
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcers
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
HealthpointCompletedVenous Leg Ulcer | Venous Stasis UlcersUnited States, Canada
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
University of TurkuUnknown
-
Oneness Biotech Co., Ltd.Taipei Veterans General Hospital, Taiwan; Taipei Medical University Shuang...RecruitingVenous Leg Ulcers (VLU)Taiwan
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Macrocure Ltd.UnknownChronic Venous Leg UlcersUnited States
Clinical Trials on Vehicle
-
Haus BioceuticalsCompletedEczema | Atopic DermatitisIndia
-
PfizerCompleted
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
LEO PharmaCompleted
-
Johns Hopkins Bloomberg School of Public HealthCompletedObesity | Childhood Obesity | Dietary Habits | Water; Lack of | Feeding Behavior | Mother-Child RelationsUnited States
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
University of British ColumbiaUnknownCicatrix | Scar | Keloid | Hypertrophic Scar | Skin Graft Scar | Skin Graft Complications | Donor Site ComplicationCanada
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States